David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024 Cash and short-term assets of $84.8 million as of December 31, 2024 Provides first quarter and full year 2025 guidance Projects full year 2025 revenue of $73 million to $85 million, driven by the strong launch of IM8 Health CHARLOTTE, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced its preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024, along with recent business updates. Management Comme

CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraisePrenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheetPrenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading genomics and consumer healthcare company, today announced a groundbreaking genomics-based partnership with Humanity Protocol, a decentralized identity verification company. This collaboration leverages Prenetics' advanced genetic testing capabilities to unde

The Next Big Thing in Wellness? IM8 Lands in the U.S. with a Star-Studded Launch. David Beckham and a world-class scientific team are putting the focus back on foundational health CHARLOTTE, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- IM8, a premium supplements brand co-founded by David Beckham, hosted its U.S. unveiling event in New York City on January 14. The two-part event featured an Inside Out Wellness session with holistic health advocate Deepak Chopra, M.D., and David Beckham, followed by An Evening with IM8 featuring stage conversations with IM8's Scientific Advisory Board (SAB) and co-founding partner of IM8, David Beckham. This event solidified the brand's U.S. presence following I

– David Beckham Co-Founded Premium Supplements Brand Sets the Standard for Science-Backed Excellence – Tested for 280+ banned substances, trusted by global athletes in WADA, NFL, NBA, MLB, PGA and more – IM8 is available at IM8health.com, shipping to 31 countries and regions CHARLOTTE, N.C., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Prenetics' IM8, a premium supplements brand co-founded by David Beckham, announces its flagship product, Daily Ultimate Essentials, has been certified to NSF Certified for Sport®, a globally recognized standard for supplement safety, quality, and transparency. This certification underscores IM8's commitment to delivering premium products that meet the highe

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics' (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. This collaboration aims to advance health and longevity through the fusion of IM8's cutting-edge innovation and Mayo Clinic's medical expertise. The collaboration will focus on creating evidence-based, clinica

Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISSCollaboration Aims to Enhance Healthspan on Earth and Improve Astronaut Health in SpaceIM8, a new premium supplements brand launched officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Prenetics' IM8 is excited to announce that its groundbreaking month-long space experiment, in partnership with the University of Oxford and supported by Space Applications Services and Metavisionaries, is now underway aboard the International Space Station (ISS). Launched via SpaceX CRS-31 on November 4th at 9:29 pm EST, the mission aims to study accelerated aging and longevity by leveraging mic

CHARLOTTE, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited, (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced that members of the Prenetics management team will participate in two upcoming investor conferences. iAccess Alpha Virtual Best Ideas Winter Conference 2024 Date: December 10-11, 2024 Location: Virtual Presentation: December 10, 2024 at 10:00am ET Webcast: https://www.webcaster4.com/Webcast/Page/3074/51539 Danny Yeung, Chief Executive Officer, will deliver a presentation on December 10, 2024, and will be joined by Stephen Lo, Chief Financial Officer, and David Vander

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and implement a capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight how Prenetics is at the forefront of cutting-edge technological advancements in health and wellness. Under the Prenetics umbre

(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government. - By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.1 - Prof. Dennis Lo is the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong (CUHK) and the Scientific Director of the Centre for Novostics. HONG KONG, June 25, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leadi

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology marketAcquisition expected to complete on or around December 30, 2022, subject to normal closing conditions LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PR

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $9.47875000 per share on the company’s 5.250% fixed-to-floating rate non-cumulative preferred stock, Series C, with a liquidation preference of $1,000 per share. Semi-annual dividend of $29.375 per share on the company’s 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company’s 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary

NEW YORK--(BUSINESS WIRE)--Two Harbors Investment Corp. (NYSE: TWO), an Agency + MSR mortgage real estate investment trust, today announced the redemption of all outstanding shares of both the company’s 7.75% Series D Cumulative Redeemable Preferred Stock (NYSE: TWO PRD)(the “Series D Preferred Stock”) and 7.50% Series E Cumulative Redeemable Preferred Stock (NYSE: TWO PRE)(“Series E Preferred Stock”). The cash redemption amount (the “Redemption Amount”) for each share of Series D Preferred Stock and Series E Preferred Stock is $25.00 plus accrued and unpaid dividends to, but not including, the redemption date for each series of March 15, 2021 (the “Redemption Date”). On the Redemp

Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D - Prenetics Global Ltd (0001876431) (Subject)

SC 13D/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13D - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

SC 13G - Prenetics Global Ltd (0001876431) (Subject)